Largest biotech by earnings
Net income for the latest fiscal year: what was left for shareholders after every cost, interest and tax. A negative figure is a loss.
Gilead Sciences leads the 24 biotech ranked by earnings, at SAR 31.9B, ahead of Amgen (SAR 28.9B) and Biogen (SAR 4.8B). Figures as of 18 Nov 2026, 15:06 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- Gilead SciencesSAR 31.9B
- Median
- -SAR 257.3M
- Combined market value
- SAR 3.19T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Earnings ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Gilead SciencesGILD · Health Care | SAR 31.9B | SAR 789.9B | SAR 636.88 | 0.28% down | 33% up | ||
| 2 | AmgenAMGN · Health Care | SAR 28.9B | SAR 918.1B | SAR 1,697.25 | 1.19% down | 34% up | ||
| 3 | BiogenBIIB · Health Care | SAR 4.8B | SAR 139.2B | SAR 941.50 | 0.08% up | 49% up | ||
| 4 | argenxARGX · Health Care | SAR 4.8B | SAR 227.2B | SAR 3,612.33 | 1.64% up | 4% up | ||
| 5 | ExelixisEXEL · Health Care | SAR 2.9B | SAR 63.3B | SAR 259.61 | 1.04% up | 63% up | ||
| 6 | Neurocrine BiosciencesNBIX · Health Care | SAR 1.8B | SAR 62.3B | SAR 615.20 | 1.15% down | 20% up | ||
| 7 | QiagenQGEN · Health Care | SAR 1.6B | SAR 38.5B | SAR 186.44 | 0.09% down | 12% up | ||
| 8 | Halozyme TherapeuticsHALO · Health Care | SAR 1.2B | SAR 41.6B | SAR 364.48 | 1.25% up | 37% up | ||
| 9 | Krystal BiotechKRYS · Health Care | SAR 768.3M | SAR 34.4B | SAR 1,159.36 | 3.53% up | 46% up | ||
| 10 | Bio-TechneTECH · Health Care | SAR 682.2M | SAR 42.9B | SAR 272.81 | 0.14% up | 26% up | ||
| 11 | RepligenRGEN · Health Care | SAR 183.4M | SAR 41.5B | SAR 649.49 | 6.76% up | 5% up | ||
| 12 | Adaptive BiotechnologiesADPT · Health Care | -SAR 223.2M | SAR 17.6B | SAR 108.89 | 1.90% up | 88% up | ||
| 13 | Twist BioscienceTWST · Health Care | -SAR 291.3M | SAR 30.3B | SAR 443.71 | 5.62% up | 340% up | ||
| 14 | CG OncologyCGON · Health Care | -SAR 603.9M | SAR 25.9B | SAR 290.50 | 1.89% down | 85% up | ||
| 15 | Kodiak SciencesKOD · Health Care | -SAR 862.6M | SAR 24.3B | SAR 371.35 | 2.27% up | 396% up | ||
| 16 | Kymera TherapeuticsKYMR · Health Care | -SAR 1.2B | SAR 39.6B | SAR 463.79 | 1.75% up | 87% up | ||
| 17 | ImmunityBioIBRX · Health Care | -SAR 1.3B | SAR 26.1B | SAR 24.51 | 4.39% up | 193% up | ||
| 18 | Scholar Rock HoldingSRRK · Health Care | -SAR 1.4B | SAR 21.9B | SAR 179.11 | 5.92% up | 14% up | ||
| 19 | ImmunovantIMVT · Health Care | -SAR 1.9B | SAR 26.2B | SAR 126.56 | 1.60% up | 43% up | ||
| 20 | CRISPR TherapeuticsCRSP · Health Care | -SAR 2.2B | SAR 15.3B | SAR 157.99 | 4.91% up | 21% down | ||
| 21 | VaxcytePCVX · Health Care | -SAR 2.9B | SAR 35.2B | SAR 222.43 | 0.17% down | 22% up | ||
| 22 | Revolution MedicinesRVMD · Health Care | -SAR 4.2B | SAR 131.5B | SAR 607.81 | 0.40% down | 131% up | ||
| 23 | BioNTechBNTX · Health Care | -SAR 4.7B | SAR 79B | SAR 318.72 | 0.13% up | 16% down | ||
| 24 | ModernaMRNA · Health Care | -SAR 10.6B | SAR 315B | SAR 778.58 | 0.37% up | 755% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Earnings is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 3.7510 SAR).
Questions and answers
Which biotech rank first by earnings?
Gilead Sciences (SAR 31.9B), Amgen (SAR 28.9B) and Biogen (SAR 4.8B) are the top three of the 24 biotech ranked by earnings as of 18 Nov 2026, 15:06 UTC.
How many biotech are in this ranking?
24 are ranked by earnings.
What are these biotech worth together?
The 24 biotech ranked by earnings have a combined market value of SAR 3.19T as of 18 Nov 2026, 15:06 UTC.
What does ranking by earnings measure?
Net income for the latest fiscal year: what was left for shareholders after every cost, interest and tax. A negative figure is a loss.
Learn how this ranking works
All markets guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
- How companies are sorted into sectors and industries
Companies are sorted into sectors and industries by classification systems. The index providers MSCI and S&P Dow Jones Indices use GICS: 11 sectors split into 25 industry groups, 74 industries and 163 sub-industries. SEC filings carry a four-digit SIC code. The two can place one company differently, because each looks at the business from its own angle.
Cite this page
Funkfolio, “Largest biotech by earnings”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=earnings
Underlying data: Yahoo Finance; SEC EDGAR.